Total Payments
$4,715
2024 Payments
$279.57
Companies
47
Transactions
237
Medicare Patients
3,289
Medicare Billing
$776,109
Payment Breakdown by Category
Food & Beverage$4,195 (89.0%)
Education$519.31 (11.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,195 | 222 | 89.0% |
| Education | $519.31 | 15 | 11.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $514.90 | 26 | $0 (2024) |
| PFIZER INC. | $377.14 | 27 | $0 (2024) |
| Janssen Biotech, Inc. | $332.11 | 13 | $0 (2024) |
| Amgen Inc. | $300.41 | 14 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $290.31 | 17 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $288.95 | 7 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $222.20 | 13 | $0 (2021) |
| Celgene Corporation | $179.99 | 17 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $178.99 | 8 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $176.36 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $279.57 | 12 | Takeda Pharmaceuticals U.S.A., Inc. ($59.71) |
| 2023 | $322.34 | 15 | AbbVie Inc. ($77.52) |
| 2022 | $427.76 | 28 | Celgene Corporation ($124.95) |
| 2021 | $491.74 | 23 | E.R. Squibb & Sons, L.L.C. ($97.45) |
| 2020 | $427.65 | 21 | Amgen Inc. ($135.46) |
| 2019 | $1,219 | 54 | Janssen Biotech, Inc. ($155.50) |
| 2018 | $928.77 | 45 | Novartis Pharmaceuticals Corporation ($170.58) |
| 2017 | $617.46 | 39 | Novartis Pharmaceuticals Corporation ($149.57) |
All Payment Transactions
237 individual payment records from CMS Open Payments — Page 2 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/27/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $24.57 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/03/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.13 | General |
| Category: Hematology | ||||||
| 11/23/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2022 | PFIZER INC. | BOSULIF (Drug), BESPONSA, PAXLOVID | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/16/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $28.90 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $10.45 | General |
| Category: Hematology | ||||||
| 11/07/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $4.24 | General |
| Category: Hematology | ||||||
| 10/12/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.38 | General |
| Category: Oncology | ||||||
| 10/03/2022 | Bayer HealthCare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $27.89 | General |
| Category: Oncology | ||||||
| 09/27/2022 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $27.97 | General |
| 09/14/2022 | Amgen Inc. | Vectibix (Biological) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: Oncology | ||||||
| 09/07/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $10.88 | General |
| Category: Hematology | ||||||
| 08/31/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $12.50 | General |
| Category: Hematology | ||||||
| 08/31/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $1.76 | General |
| Category: Hematology | ||||||
| 08/17/2022 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $25.68 | General |
| Category: Oncology | ||||||
| 08/11/2022 | MorphoSys, US Inc. | MONJUVI (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Oncology | ||||||
| 08/03/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.91 | General |
| Category: Oncology | ||||||
| 07/18/2022 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $14.02 | General |
| Category: Hematology | ||||||
| 07/13/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $9.73 | General |
| Category: Hematology | ||||||
| 07/13/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $4.53 | General |
| Category: Hematology | ||||||
| 06/15/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $21.53 | General |
| Category: Oncology | ||||||
| 05/18/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Education | In-kind items and services | $12.06 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2022 | Celgene Corporation | ONUREG (Drug) | Food and Beverage | Cash or cash equivalent | $12.06 | General |
| Category: Oncology | ||||||
| 04/12/2022 | Celgene Corporation | ONUREG (Drug) | Food and Beverage | Cash or cash equivalent | $12.61 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 800 | 7,662 | $481,538 | $177,240 |
| 2022 | 19 | 872 | 8,245 | $498,522 | $188,102 |
| 2021 | 15 | 723 | 8,868 | $538,148 | $213,759 |
| 2020 | 17 | 894 | 9,322 | $568,230 | $197,008 |
Total Patients
3,289
Total Services
34,097
Medicare Billing
$776,109
Procedure Codes
76
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 231 | 592 | $135,568 | $53,712 | 39.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 156 | 531 | $121,781 | $52,709 | 43.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 18 | 176 | $55,088 | $19,525 | 35.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 25 | 170 | $26,350 | $8,842 | 33.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 28 | 95 | $30,400 | $6,697 | 22.0% |
| J1750 | Injection, iron dextran, 50 mg | Office | 2023 | 18 | 486 | $12,636 | $6,312 | 49.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 29 | 29 | $12,528 | $4,690 | 37.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 20 | 186 | $13,020 | $4,475 | 34.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 11 | 177 | $11,682 | $4,197 | 35.9% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 18 | 50 | $11,000 | $3,752 | 34.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $8,256 | $3,007 | 36.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 49 | 267 | $12,800 | $2,964 | 23.2% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 21 | 151 | $6,946 | $2,500 | 36.0% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 14 | 175 | $5,600 | $1,876 | 33.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 14 | 90 | $4,320 | $1,169 | 27.1% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 38 | 191 | $1,910 | $225.31 | 11.8% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 34 | 382 | $7,684 | $192.96 | 2.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 25 | 1,948 | $1,948 | $190.86 | 9.8% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 15 | 1,863 | $1,863 | $139.95 | 7.5% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 12 | 79 | $158.00 | $63.60 | 40.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 243 | 719 | $164,549 | $69,707 | 42.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 156 | 529 | $121,232 | $51,365 | 42.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 20 | 178 | $55,714 | $20,544 | 36.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 51 | 104 | $33,280 | $6,951 | 20.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 26 | 118 | $18,290 | $6,693 | 36.6% |
About Dr. James Tsai, M.D
Dr. James Tsai, M.D is a Hematology & Oncology healthcare provider based in Hemet, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1437152857.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Tsai, M.D has received a total of $4,715 in payments from pharmaceutical and medical device companies, with $279.57 received in 2024. These payments were reported across 237 transactions from 47 companies. The most common payment nature is "Food and Beverage" ($4,195).
As a Medicare-enrolled provider, Tsai has provided services to 3,289 Medicare beneficiaries, totaling 34,097 services with total Medicare billing of $776,109. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Hemet, CA
- Active Since 05/31/2005
- Last Updated 08/27/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1437152857
Products in Payments
- OPDIVO (Biological) $241.14
- IMBRUVICA (Drug) $206.55
- VELCADE (Drug) $205.20
- KEYTRUDA (Biological) $204.00
- JEVTANA (Drug) $119.07
- XTANDI (Drug) $113.24
- BENDEKA (Drug) $112.51
- Lonsurf (Drug) $108.91
- KISQALI (Drug) $101.70
- JADENU (Drug) $101.02
- Nubeqa (Drug) $93.51
- DARZALEX (Biological) $90.47
- IMFINZI (Drug) $88.44
- JAKAFI (Drug) $88.34
- TAGRISSO (Drug) $87.92
- REBLOZYL (Biological) $77.07
- Kyprolis (Biological) $68.03
- IBRANCE (Drug) $64.10
- AFINITOR (Drug) $63.99
- Bavencio (Biological) $59.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.